2 Biotechs To Avoid, 1 To Buy
Motley Fool
3 Biotechs Targeting Breast Cancer
Seeking Alpha
Galena pays $10M upfront to license Abstral, a treatment for severe episodes of cancer pain
Yahoo/AP
100% Upside on these Bio-techs
Motley Fool
Galena Biopharma Might Soar In 2013
Seeking Alpha
Biotech Under The Electron Microscope: What's In The Pipeline And Lessons To Be Learned
Seeking Alpha

